Ultragenyx Announces First Patient Dosed in Pivotal Phase 3 Aspire Study Evaluating GTX-102 in Angelman Syndrome
Portfolio Pulse from
Ultragenyx has dosed the first patient in its Phase 3 Aspire study for GTX-102, targeting Angelman Syndrome. The company plans to start the Aurora study in 2025 to evaluate GTX-102 in other genotypes and age groups.
December 19, 2024 | 9:30 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Ultragenyx has initiated a pivotal Phase 3 study for GTX-102 in Angelman Syndrome, marking a significant step in its clinical development. The company is also planning a new study, Aurora, for 2025.
The initiation of a Phase 3 study is a critical milestone in drug development, indicating progress towards potential market approval. This news is likely to positively impact Ultragenyx's stock as it demonstrates advancement in their clinical pipeline.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100